{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T20:14:16Z","timestamp":1794687256936,"version":"4.9.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Phase I\/IIa study of tominersen","award":["NCT02519036"],"award-info":[{"award-number":["NCT02519036"]}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"crossref"}]},{"name":"F. Hoffmann\u2013La Roche Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It is unknown whether alterations in EEG brain activity caused by Huntington\u2019s disease may be responsive to huntingtin-lowering treatment. We analysed EEG recordings of 46 patients (mean age\u2009=\u200947.02 years; standard deviation\u2009=\u200910.19 years; 18 female) with early-manifest Stage 1 Huntington\u2019s disease receiving the huntingtin-lowering antisense oligonucleotide tominersen for 4 months or receiving placebo as well as 39 healthy volunteers (mean age\u2009=\u200944.48 years; standard deviation\u2009=\u200912.94; 22 female) not receiving treatment. Patients on tominersen showed increased resting-state activity within a 4\u20138\u2005Hz frequency range compared with patients receiving placebo (cluster-based permutation test, P\u2009&amp;lt;\u20090.05). The responsive frequency range overlapped with EEG activity that was strongly reduced in Huntington\u2019s disease compared with healthy controls (cluster-based permutation test, P\u2009&amp;lt;\u20090.05). The underlying mechanisms of the observed treatment-related increase are unknown and may reflect neural plasticity as a consequence of the molecular pathways impacted by tominersen treatment.<\/jats:p>\n               <jats:p>Hawellek et al. report that patients with Huntington\u2019s disease treated with the huntingtin-lowering antisense oligonucleotide tominersen exhibited increased EEG power in the theta\/alpha frequency range. The underlying mechanisms of the observed changes are unknown and may reflect neural plasticity as a consequence of the molecular pathways impacted by tominersen treatment.<\/jats:p>","DOI":"10.1093\/braincomms\/fcac149","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:10:48Z","timestamp":1654780248000},"source":"Crossref","is-referenced-by-count":18,"title":["Changes in brain activity with tominersen in early-manifest Huntington\u2019s disease"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-3351","authenticated-orcid":false,"given":"D J","family":"Hawellek","sequence":"first","affiliation":[{"name":"Roche, Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Basel 4070 , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Garces","sequence":"additional","affiliation":[{"name":"Roche, Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Basel 4070 , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A H","family":"Meghdadi","sequence":"additional","affiliation":[{"name":"Advanced Brain Monitoring Inc. , Carlsbad, CA 92008 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Waninger","sequence":"additional","affiliation":[{"name":"Advanced Brain Monitoring Inc. , Carlsbad, CA 92008 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Smith","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc. , Carlsbad, CA 92010 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Manchester","sequence":"additional","affiliation":[{"name":"Roche, Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Basel 4070 , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Schobel","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd , Basel 4070 , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7875-2988","authenticated-orcid":false,"given":"J F","family":"Hipp","sequence":"additional","affiliation":[{"name":"Roche, Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Basel 4070 , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"2022062901504294100_fcac149-B1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2022062901504294100_fcac149-B2","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2022062901504294100_fcac149-B3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"2022062901504294100_fcac149-B4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"2022062901504294100_fcac149-B5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-444-52014-2.00004-5","article-title":"Huntington's disease\u2014neuropathology","volume":"100","author":"Vonsattel","year":"2011","journal-title":"Handb Clin Neurol"},{"key":"2022062901504294100_fcac149-B6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/7854_2014_354","article-title":"The neuropathology of Huntington's disease","volume":"22","author":"Waldvogel","year":"2015","journal-title":"Curr Top Behav Neurosci"},{"key":"2022062901504294100_fcac149-B7","first-page":"jnumed.121.262709","article-title":"Synaptic vesicle glycoprotein 2A is affected in the CNS of Huntington's disease mice and post-mortem human HD brain","volume":"63","author":"Bertoglio","year":"2021","journal-title":"J Nucl Med"},{"key":"2022062901504294100_fcac149-B8","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1212\/WNL.0000000000012969","article-title":"Synaptic damage and its clinical correlates in people with early Huntington disease: a PET study","volume":"98","author":"Delva","year":"2022","journal-title":"Neurology"},{"key":"2022062901504294100_fcac149-B9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fneur.2017.00091","article-title":"Quantitative electroencephalographic biomarkers in preclinical and human studies of Huntington's disease: are they fit-for-purpose for treatment development?","volume":"8","author":"Leuchter","year":"2017","journal-title":"Front Neurol"},{"key":"2022062901504294100_fcac149-B10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.24495","article-title":"Sleep deficits but no metabolic deficits in premanifest Huntington's disease","volume":"78","author":"Lazar","year":"2015","journal-title":"Ann Neurol"},{"issue":"1-2","key":"2022062901504294100_fcac149-B11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jns.2014.06.035","article-title":"Alpha-theta border EEG abnormalities in preclinical Huntington's disease","volume":"344","author":"Ponomareva","year":"2014","journal-title":"J Neurol Sci"},{"key":"2022062901504294100_fcac149-B12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00702-010-0491-7","article-title":"Comparative EEG mapping studies in Huntington's disease patients and controls","volume":"117","author":"Painold","year":"2010","journal-title":"J Neural Transm (Vienna)"},{"key":"2022062901504294100_fcac149-B13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s00415-010-5852-5","article-title":"EEG low-resolution brain electromagnetic tomography (LORETA) in Huntington's disease","volume":"258","author":"Painold","year":"2011","journal-title":"J Neurol"},{"key":"2022062901504294100_fcac149-B14","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"key":"2022062901504294100_fcac149-B15","doi-asserted-by":"crossref","first-page":"156869","DOI":"10.1155\/2011\/156869","article-title":"Fieldtrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data","volume":"2011","author":"Oostenveld","year":"2011","journal-title":"Comput Intell Neurosci"},{"key":"2022062901504294100_fcac149-B16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1109\/72.761722","article-title":"Fast and robust fixed-point algorithms for independent component analysis","volume":"10","author":"Hyvarinen","year":"1999","journal-title":"IEEE Trans Neural Netw"},{"key":"2022062901504294100_fcac149-B17","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.neuroimage.2011.01.055","article-title":"An improved index of phase-synchronization for electrophysiological data in the presence of volume-conduction, noise and sample-size bias","volume":"55","author":"Vinck","year":"2011","journal-title":"Neuroimage"},{"key":"2022062901504294100_fcac149-B18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nn.3101","article-title":"Large-scale cortical correlation structure of spontaneous oscillatory activity","volume":"15","author":"Hipp","year":"2012","journal-title":"Nat Neurosci"},{"key":"2022062901504294100_fcac149-B19","doi-asserted-by":"crossref","first-page":"17072","DOI":"10.1523\/JNEUROSCI.1625-13.2013","article-title":"Altered intrinsic neuronal interactions in the visual cortex of the blind","volume":"33","author":"Hawellek","year":"2013","journal-title":"J Neurosci"},{"key":"2022062901504294100_fcac149-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hbm.1058","article-title":"Nonparametric permutation tests for functional neuroimaging: a primer with examples","volume":"15","author":"Nichols","year":"2002","journal-title":"Hum Brain Mapp"},{"key":"2022062901504294100_fcac149-B21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1191\/0962280203sm341ra","article-title":"Controlling the familywise error rate in functional neuroimaging: a comparative review","volume":"12","author":"Nichols","year":"2003","journal-title":"Stat Methods Med Res"},{"key":"2022062901504294100_fcac149-B22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","article-title":"Forming inferences about some intraclass correlation coefficients","volume":"1","author":"McGraw","year":"1996","journal-title":"Psychol Met"},{"key":"2022062901504294100_fcac149-B23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.neuroimage.2009.10.003","article-title":"Complex network measures of brain connectivity: uses and interpretations","volume":"52","author":"Rubinov","year":"2010","journal-title":"Neuroimage"},{"key":"2022062901504294100_fcac149-B24","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","article-title":"Motor, cognitive, and functional declines contribute to a single progressive factor in early HD","volume":"89","author":"Schobel","year":"2017","journal-title":"Neurology"},{"key":"2022062901504294100_fcac149-B25","doi-asserted-by":"crossref","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci Transl Med"},{"key":"2022062901504294100_fcac149-B26","first-page":"RRN1192","article-title":"QEEG measures in Huntington's disease: a pilot study","volume":"2","author":"Hunter","year":"2010","journal-title":"PLoS Curr"},{"key":"2022062901504294100_fcac149-B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jpsychores.2004.02.001","article-title":"Sleep and quantitative EEG in neurodegenerative disorders","volume":"56","author":"Petit","year":"2004","journal-title":"J Psychosom Res"},{"key":"2022062901504294100_fcac149-B28","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.clinph.2004.01.001","article-title":"EEG Dynamics in patients with Alzheimer's disease","volume":"115","author":"Jeong","year":"2004","journal-title":"Clin Neurophysiol"},{"key":"2022062901504294100_fcac149-B29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neuron.2006.09.020","article-title":"Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology","volume":"52","author":"Uhlhaas","year":"2006","journal-title":"Neuron"},{"key":"2022062901504294100_fcac149-B30","doi-asserted-by":"crossref","first-page":"14332","DOI":"10.1073\/pnas.1402773111","article-title":"Alpha and gamma oscillations characterize feedback and feedforward processing in monkey visual cortex","volume":"111","author":"van Kerkoerle","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022062901504294100_fcac149-B31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.cub.2012.10.020","article-title":"Layer-specific entrainment of gamma-band neural activity by the alpha rhythm in monkey visual cortex","volume":"22","author":"Spaak","year":"2012","journal-title":"Curr Biol"},{"key":"2022062901504294100_fcac149-B32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.neuron.2008.09.014","article-title":"Entrainment of neocortical neurons and gamma oscillations by the hippocampal theta rhythm","volume":"60","author":"Sirota","year":"2008","journal-title":"Neuron"},{"key":"2022062901504294100_fcac149-B33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"2022062901504294100_fcac149-B34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/clpt.1992.123","article-title":"Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time","volume":"52","author":"Friedman","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"2022062901504294100_fcac149-B35","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Mol Psychiatry"},{"key":"2022062901504294100_fcac149-B36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fphar.2016.00348","article-title":"Effects of ketamine on resting-state EEG activity and their relationship to perceptual\/dissociative symptoms in healthy humans","volume":"7","author":"de la Salle","year":"2016","journal-title":"Front Pharmacol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcac149\/43990046\/fcac149.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/3\/fcac149\/44277255\/fcac149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/3\/fcac149\/44277255\/fcac149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:51:18Z","timestamp":1656467478000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcac149\/6604797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcac149","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,5,2]]},"article-number":"fcac149"}}